Reuters logo
BRIEF-Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre
November 7, 2017 / 10:18 AM / 11 days ago

BRIEF-Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre

Nov 7 (Reuters) - PHARMA MAR SA:

* SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA

* TO RECEIVE A NON-DISCLOSED UPFRONT PAYMENT AND TO BE ELIGIBLE FOR ADDITIONAL REMUNERATIONS UPON ACHIEVING REGULATORY AND SALES MILESTONES

* TO RETAIN EXCLUSIVE PRODUCTION RIGHTS AND TO SELL THE PRODUCT TO BORYUNG PHARM FOR COMMERCIAL USE

* ZEPSYRE IS CURRENTLY IN LATE-STAGE CLINICAL DEVELOPMENT FOR PLATINUM-RESISTANT OVARIAN CANCER AND FOR SMALL-CELL LUNG CANCER

Source text: bit.ly/2yb7aqY

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below